Navigating 8 Analyst Ratings For HealthEquity
Portfolio Pulse from Benzinga Insights
HealthEquity (NASDAQ:HQY) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. The average 12-month price target is $102.5, slightly down from $103. Analysts have maintained or adjusted their ratings based on market conditions and company performance. HealthEquity shows strong financial metrics, including a 23.15% revenue growth rate and a net margin of 11.94%.
September 20, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HealthEquity has received a mix of bullish and somewhat bullish ratings from analysts, with a slight decrease in the average price target to $102.5. The company's strong financial performance, including a 23.15% revenue growth rate and a net margin of 11.94%, supports a positive outlook.
The majority of analysts have a somewhat bullish outlook on HealthEquity, with a slight decrease in the average price target. The company's strong financial metrics, such as high revenue growth and net margin, suggest a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100